Bioinformatics Data Scientist

Integrated DNA Technologies expands synthetic biology portfolio with Ansa Biotechnologies' Clonal DNA and XL Clonal DNA products. New collaboration empowers customers with sequence-perfect constructs as long as 50 kb SUNNYVALE and EMERYVILLE, Calif. - Jan. 14, 2026 - Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics, and Ansa Biotechnologies, Inc., a trusted partner for DNA synthesis, today announced a strategic collaboration that adds new complementary capabilities to IDT's synthetic biology portfolio. Ansa's Clonal DNA and XL Clonal DNA products, ranging from 100 bp to 50 kb, will be made available to IDT customers, enabling researchers to design and assemble longer, more complex constructs for next-generation cell and gene therapy discovery, vaccine research, and agrigenomics applications. By joining forces, IDT will pair its nearly 40-year legacy of quality and service, as well as its global presence, with Ansa's breakthrough enzymatic DNA synthesis platform to accelerate the delivery of challenging motifs, higher complexity, and longer constructs. The partnership prioritizes the delivery of a new standard for speed, precision, and reliability. Each sequence is rigorously verified and optimized for GC content, homopolymers, and repetitive elements to give researchers confidence that their designs are accurate, which helps to minimize rework, troubleshooting, and downstream risk. "Customers face unprecedented complexity in their research, and they deserve solutions that make progress simpler and faster," said IDT President Ajay Gannerkote. "IDT's partnership with Ansa reflects the combination of proven reliability and trust with innovation in synthetic biology to deliver exactly that. This collaboration will help ensure researchers can come to IDT for their needs across every dimension of complexity, enabling breakthroughs that truly matter." Jason T. Gammack, Chief Executive Officer of Ansa, commented: "Ansa was founded to solve the hardest problems in DNA synthesis: length, complexity, and reliability. Through our collaboration with IDT, we are dismantling long-standing technical barriers and enabling more researchers worldwide to push the boundaries of science with greater confidence and without compromise." Ansa is redefining what is possible in synthetic biology through its proprietary enzymatic platform, which provides both the length and complexity needed to design and assemble critical DNA constructs at scale. Ansa's sustainable approach uses no harsh chemicals, preserving DNA integrity while enabling the synthesis of longer, more complex sequences. Exclusively manufactured in the United States, Ansa's DNA products integrate seamlessly into existing workflows while empowering the next wave of biological discovery. The company is guided by a rigorous biosecurity framework and full compliance with the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening. IDT customers can purchase Ansa Clonal DNA and XL Clonal DNA products at www.idtdna.com/complexDNA. Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. Bio-IT World Inc work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Its vision of enabling researchers to rapidly move from the lab to life-changing advances reflects its ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Visit www.Danaher.com to learn more about Danaher, a leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health. For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X,, YouTube, Instagram and Bluesky. Disclaimer: RUO - For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations. About Ansa Biotechnologies Ansa Biotechnologies is redefining DNA synthesis with a bold commitment to quality, customer satisfaction, and success. The Ansa On-Time Guarantee is simple and straightforward: your complete order on time or it's free. This unprecedented level of service reliability and predictability is made possible by Ansa's dedicated team of experts and proprietary enzymatic synthesis platform, which can rapidly and accurately produce even the highly complex DNA elements that stymie legacy approaches. Products are delivered as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. Headquartered in Emeryville, Calif., Ansa is empowering a global community of scientists to accelerate breakthroughs in healthcare, life sciences, and other industries powered by synthetic DNA. Discover more at ansabio.com or follow the company on X, Bluesky, and LinkedIn. Ansa Biotechnologies and the Ansa Biotechnologies logo are trademarks of Ansa Biotechnologies, Inc.

Ansa Biotechnologies appoints Geoff Hamilton as Chief Financial Officer and Chief Business Officer. Ansa Biotechnologies announced the appointment of Geoff Hamilton as Chief Financial Officer and Chief Business Officer. EMERYVILLE, Calif. - Dec. 9, 2025 - Ansa Biotechnologies Inc., the trusted partner for DNA synthesis, today announced the appointment of Geoff Hamilton as Chief Financial Officer and Chief Business Officer. Mr. Hamilton will report directly to CEO Jason T. Gammack and lead the company's financial operations, corporate strategy, and key partnerships as Ansa accelerates its commercial expansion across the biotechnology, synthetic biology, and pharmaceutical sectors. Ansa's first year of commercialization has been driven by surging demand for the only long, complex, sequence-perfect, and guaranteed synthetic DNA on the market. Legacy chemical synthesis methods limit researchers to short, simple DNA constructs, but scientists require much larger and more intricate designs for emerging applications in cell and gene therapy, genome engineering, bioproduction, and advanced biologics. Ansa is addressing this need with its enzymatic platform, enabling accurate, verified clonal DNA up to 50 kilobases and setting a new standard for reliability through the industry-first Ansa On-Time Guarantee. "Geoff knows how to build momentum in markets that are shifting beneath our feet. He's scaled teams, products, and businesses through industry-defining transitions; this is exactly where Ansa is right now," said Mr. Gammack. "Bringing Geoff on board accelerates our ability to push the boundaries of what researchers can design, order, and expect from their synthesis partners. He's joining a company intent on redefining the rules for synthetic biology." Mr. Hamilton brings more than 25 years of leadership experience across the life sciences and medical device sectors. He co-founded and served as CEO of Stemson Therapeutics, a pioneering cell therapy company developing curative treatments for hair loss. Before that, he held senior leadership roles at Illumina, Life Technologies, and Stryker, where he led financial planning, commercial strategy, high-value partnerships, product development, and global launch initiatives that shaped multiple high-growth industry segments. He holds a bachelor of science in business administration from the University of North Carolina at Chapel Hill. Mr. Hamilton volunteers as a coach and mentor for The Honor Foundation, supporting career transitions for U.S. Special Operations veterans. "I'm excited to join Ansa at such a critical point in the evolution of our field. The DNA synthesis market is approaching a transformation comparable to the sequencing boom two decades ago," said Mr. Hamilton. "Thanks to the remarkable commercial traction and technological breakthroughs Ansa has achieved during the past year, we're positioned to lead the next era of genome writing. Researchers will finally be able to move beyond fragment-scale limitations and fully embrace genome-scale engineering. Our highly reliable manufacturing platform, transparent pricing, and guaranteed service model set a unique benchmark for what customers should expect from their DNA synthesis partners." Exclusively manufactured in the United States, Ansa's DNA products integrate seamlessly into existing workflows while empowering the next wave of biological discovery. The company is guided by a rigorous biosecurity framework and full compliance with the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening. For more information about Ansa's products, visit www.ansabio.com/products. About Ansa Biotechnologies Ansa Biotechnologies is redefining DNA synthesis with a bold commitment to quality, customer satisfaction, and success. The Ansa On-Time Guarantee is simple and straightforward: your complete order on time or it's free. This unprecedented level of service reliability and predictability is made possible by Ansa's dedicated team of experts and proprietary enzymatic synthesis platform, which can rapidly and accurately produce even the highly complex DNA elements that stymie legacy approaches. Products are delivered as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. Headquartered in Emeryville, Calif., Ansa is empowering a global community of scientists to accelerate breakthroughs in healthcare, life sciences, and other industries powered by synthetic DNA. Discover more at ansabio.com or follow the company on X, Bluesky, and LinkedIn. Ansa Biotechnologies and the Ansa Biotechnologies logo are trademarks of Ansa Biotechnologies, Inc.

Ansa Biotechnologies launches longest sequence-perfect synthetic DNA product. Ansa Biotechnologies, a company specializing in advanced DNA synthesis, announced the global launch of its 50 kilobase (kb) Clonal DNA product, now the longest sequence-perfect synthetic DNA commercially available. Powered by Ansa's proprietary enzymatic DNA synthesis platform, the new product allows researchers to design and receive complete, error-free DNA constructs within 25 days or less, supported by the company's On-Time Guarantee - the only such assurance currently offered in the industry. Traditional chemical synthesis methods typically reach their limit at about 10 kb, requiring researchers to manually assemble fragments. This process is time-consuming and error-prone. Ansa's enzymatic platform bypasses these limitations by enabling direct synthesis of long, complex sequences with higher precision and reduced environmental impact. Each construct undergoes long-read sequencing and proprietary informatics-based verification to ensure sequence accuracy. Under the Ansa On-Time Guarantee, customers who do not receive their orders within the committed timeline are eligible to receive the DNA free of charge. "Ansa has provided us with extremely long and complex constructs we couldn't get anywhere else," said Dr. Molly Gasperini, Associate Director of Genome Engineering at the Allen Institute's Seattle Hub for Synthetic Biology. "For sequences as long as 50 kb, other providers often reject or quote lengthy delivery times. Without Ansa, we couldn't obtain them so efficiently, affordably, and reliably - or at all." The product launch follows a successful early access program involving over 20 leading research organizations. Participants applied Ansa's long DNA constructs to projects in synthetic genomics, metabolic engineering, agriculture, and cell and gene therapy, overcoming long-standing technical barriers in gene synthesis. The ultra-long, fully verified constructs are now available worldwide, priced from $0.28 per base pair with turnaround times under 25 business days. Ansa employs a transparent, length-based pricing model, where the per-base cost decreases as sequence length increases. "We are very excited about the Ansa technology, which has derisked timelines for creating our TARGATT donor plasmids," said Dr. Dolores Baksh, CEO of Applied StemCell. "Ansa's large DNA synthesis capabilities align well with our TARGATT technology, which enables efficient, site-specific insertion of complex constructs into mammalian cells." "For years, scientists have been limited by what they could build, not what they could imagine," added Jason T. Gammack, CEO of Ansa Biotechnologies. "By delivering 50 kb sequence-perfect DNA in weeks, and guaranteeing it on time, we're unlocking the next era of biological design." The 50 kb Clonal DNA launch follows Ansa's recent $54.5 million Series B financing and continued commercial growth. All products are manufactured in the United States and adhere to the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening.